Sosei Heptares to regain global rights to muscarinic agonist programs
Shares of Japan’s Sosei Group (TYO: 4565) closed down 3.3% at 1,711 yen today, after it revealed it is to regain the worldwide rights to previously out-licensed muscarinic agonist programs.
In April 2016 the program was licensed to Allergan, but AbbVie (NYSE: ABBV) acquired the company in May 2020. Under the deal Allergan licensed exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists (M4, M1 and dual M1/M4 agonists) in development for the treatment of major neurological disorders, including Alzheimer’s disease.
This decision to return worldwide rights was based on business decisions regarding AbbVie’s pipeline strategy and not on any efficacy, safety or other data related to the collaboration programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze